ATLANTA, October 2, 2018 – Micron Biomedical, Inc. (Micron) recently completed a feasibility study with one of its commercial partners, a top-10 pharmaceutical company. The study consisted of developing a dissolving microneedle patch with specific design attributes to meet the partner’s unique delivery requirements and to assess the microneedle patch in in-vitro and in-vivo experiments. The study demonstrated the suitability of Micron’s microneedle patch technology to address the unique challenges posed by the partner’s specifications. Discussions are ongoing between Micron and its partner to build upon the success of the feasibility study and to continue the pre-clinical development of this novel dissolving microneedle patch.
Menu